跳至主要内容
临床试验/JPRN-UMIN000031651
JPRN-UMIN000031651招募中未知

Strategic Trial for the Prevention of Progression of Overt Diabetic Kidney Disease by GLP-1receptor agonists and SGLT2 inhibitors in Okinawa - STOPPER in OKINAWA

Sunagawa Medical Clinic0 个研究点目标入组 80 人开始时间: 2018年4月2日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Diabetes with complications requiring hospitalization such as diabetic ketoacidosis 2. Severe heart failure, severe arrhythmia, angina pectoris, myocardial infarction, stroke developed within 6 months before the start of the study 3. Pregnant women or patients who may be pregnant and breast-feeding patients 4. Ingestion of SGLT2 inhibitor 5. Have a history of having serious side effects with GLP-1 receptor agonist and SGLT2 inhibitor 6. Patients who had positive urinary occult blood test at least twice within 6 months 7. Patients with malignant tumor complications 8. Patients complicated of mental illness without self-determination ability 9. Other patients judged inappropriate by the attending physician

研究者

发起方
Sunagawa Medical Clinic

相似试验